Publication date: Dec 08, 2024
Background and Objectives: The epidemiological data regarding mortality rates of adults with sarcoidosis and non-ischemic cardiovascular disease (CVD) are limited. A retrospective observational analysis was conducted to identify trends and disparities related to sarcoidosis and non-ischemic cardiovascular disease mortality among the adult US population from 1999 to 2022. Methods: We used the Centers for Disease Control and Prevention (CDC) WONDER database to extract death certificate data for the adult US population (≥25 years). The age-adjusted mortality rates (AAMRs) per 100,000 persons were calculated, and annual percent changes (APCs) were determined using Joinpoint. Results: Between 1999 and 2022, 23,642 deaths were identified related to non-ischemic CVD + sarcoidosis. The overall AAMR increased from 0. 2 (95% CI, 0. 2 to 0. 3) in 1999 to 0. 5 (95% CI, 0. 5 to 0. 6) in 2022. Females had a higher AAMR than males (0. 6 vs. 0. 5). Non-Hispanic (NH) blacks had the highest AAMR, followed by NH whites and Hispanic or Latinos. The southern region had the highest AAMR (0. 7: 95% CI, 0. 6-0. 7), followed by the Midwest (0. 6, 95% CI, 0. 54-0. 669), the Northeast (0. 5, 95% CI, 0. 5 to 0. 6), and the West (0. 4; 95% CI, 0. 3-0. 4). Urban and rural areas had comparable mortality rates (0. 5 vs. 0. 6). People aged 65+ had the highest AAMRs. Conclusions: The overall mortality rates for non-ischemic CVD and sarcoidosis have increased in the US from 1999 to 2022. Females and NH blacks had higher AAMRs, while a minimal variation was observed based on geographical regions. Early diagnosis and prompt management are the keys to reducing the mortality burden of non-ischemic CVD plus sarcoidosis.
Open Access PDF
Concepts | Keywords |
---|---|
Females | cardiovascular disease |
Latinos | COVID-19 |
Midwest | ethnicity |
Pandemic | gender |
geographic location | |
sarcoidosis |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Sarcoidosis |
disease | MESH | Cardiovascular Disease |
disease | MESH | COVID-19 Pandemic |
disease | MESH | death |
drug | DRUGBANK | Coenzyme M |
disease | MESH | heart failure |
disease | MESH | cardiac arrest |
disease | MESH | atrioventricular blocks |
disease | IDO | blood |
disease | MESH | obesity |
disease | MESH | hyperlipidemia |
disease | MESH | ischemic heart diseases |
drug | DRUGBANK | Methionine |
disease | MESH | inflammation |
disease | MESH | scarring |
disease | MESH | infection |
disease | MESH | granuloma |
disease | MESH | autoimmune diseases |
drug | DRUGBANK | Flunarizine |
disease | MESH | unemployment |
disease | IDO | country |
disease | MESH | complications |
disease | MESH | morbidity |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | MESH | Sudden Death |
drug | DRUGBANK | Elm |
disease | MESH | cancer |
disease | MESH | Rheumatic Diseases |
disease | MESH | Musculoskeletal Diseases |
disease | MESH | Myocarditis |
disease | IDO | susceptibility |
drug | DRUGBANK | Medical air |
pathway | REACTOME | Release |
disease | MESH | Pulmonary Sarcoidosis |